Gharavi Ali G, Moldoveanu Zina, Wyatt Robert J, Barker Catherine V, Woodford Susan Y, Lifton Richard P, Mestecky Jiri, Novak Jan, Julian Bruce A
Department of Medicine, Columbia University College of Physicians and Surgeons, 630 W 168th Street, P&S 10-445 New York, New York 10032, USA.
J Am Soc Nephrol. 2008 May;19(5):1008-14. doi: 10.1681/ASN.2007091052. Epub 2008 Feb 13.
IgA nephropathy (IgAN) is a complex trait determined by genetic and environmental factors. Most IgAN patients exhibit a characteristic undergalactosylation of the O-glycans of the IgA1 hinge region, which promotes formation and glomerular deposition of immune complexes. It is not known whether this aberrant glycosylation is the result of an acquired or inherited defect, or whether the presence of aberrant IgA1 glycoforms alone can produce IgAN. A newly validated lectin enzyme-linked immunosorbent assay (ELISA) was used to determine the serum level of galactose-deficient IgA1 (Gd-IgA1) in a cohort of 89 IgAN patients and 266 of their relatives. High Gd-IgA1 levels (> or =95th percentile for controls) were observed in all 5 available patients with familial IgAN, in 21 of 45 (47%) of their at-risk relatives (assuming autosomal dominant inheritance), and in only 1 of 19 (5%) of unrelated individuals who married into the family. This provides evidence that abnormal IgA1 glycosylation is an inherited rather than acquired trait. Similarly, Gd-IgA1 levels were high in 65 of 84 (78%) patients with sporadic IgAN and in 50 of 202 (25%) blood relatives. Heritability of Gd-IgA1 was estimated at 0.54 (P = 0.0001), and segregation analysis suggested the presence of a major dominant gene on a polygenic background. Because most relatives with abnormal IgA1 glycoforms were asymptomatic, additional cofactors must be required for IgAN to develop. The fact that abnormal IgA1 glycosylation clusters in most but not all families suggests that measuring Gd-IgA1 may help distinguish patients with different pathogenic mechanisms of disease.
IgA肾病(IgAN)是一种由遗传和环境因素决定的复杂性状。大多数IgAN患者的IgA1铰链区O-聚糖存在特征性的半乳糖基化不足,这促进了免疫复合物的形成和肾小球沉积。目前尚不清楚这种异常糖基化是获得性缺陷还是遗传性缺陷的结果,也不清楚仅异常IgA1糖型的存在是否会导致IgAN。一项新验证的凝集素酶联免疫吸附测定(ELISA)用于测定89例IgAN患者及其266名亲属队列中的半乳糖缺乏IgA1(Gd-IgA1)血清水平。在所有5例可获得的家族性IgAN患者、45例(47%)有患病风险的亲属(假设为常染色体显性遗传)中的21例以及仅19例(5%)与该家族通婚的无血缘关系个体中,均观察到高Gd-IgA1水平(>或=对照组第95百分位数)。这提供了证据表明异常IgA1糖基化是一种遗传而非获得性性状。同样,84例(78%)散发性IgAN患者中的65例以及202名血亲中的50例(25%)Gd-IgA1水平也较高。Gd-IgA1的遗传度估计为0.54(P = 0.0001),分离分析表明在多基因背景上存在一个主要的显性基因。由于大多数具有异常IgA1糖型的亲属无症状,因此IgAN的发生必定还需要其他辅助因素。异常IgA1糖基化在大多数但并非所有家族中聚集的事实表明,检测Gd-IgA1可能有助于区分具有不同疾病致病机制的患者。